3 results match your criteria: "University Medical Center of the Johannes Gutenberg University (JGU) Mainz[Affiliation]"
New insights for the development of efficient DNA vaccines.
Microb Biotechnol
November 2024
Department of Dermatology, University Medical Center of the Johannes Gutenberg University (JGU) Mainz, Mainz, Germany.
Despite the great potential of DNA vaccines for a broad range of applications, ranging from prevention of infections, over treatment of autoimmune and allergic diseases to cancer immunotherapies, the implementation of such therapies for clinical treatment is far behind the expectations up to now. The main reason is the poor immunogenicity of DNA vaccines in humans. Consequently, the improvement of the performance of DNA vaccines in vivo is required.
View Article and Find Full Text PDFTranscriptional Targeting of Dendritic Cells Using an Optimized Human Gene Promoter.
Int J Mol Sci
November 2023
Pharmaceutical Biotechnology, Department of Pharmacy, Center for NanoScience, Ludwig-Maximilians-Universität (LMU) Munich, 81377 Munich, Germany.
Article Synopsis
- Research on the tumor microenvironment (TME) has led to new cancer treatment approaches like gene-based immunotherapy, which targets immune responses against tumors.
- DNA vaccines aim to stimulate anti-tumor T cell responses by activating antigen-presenting cells, and optimizing their delivery and effectiveness is essential.
- A study tested a novel DNA construct (pFscnLuc) designed for dendritic cells, showing increased activity in these immune cells compared to a standard vector in both cell culture and mouse models, particularly in the spleen.
Lipoamino bundle LNPs for efficient mRNA transfection of dendritic cells and macrophages show high spleen selectivity.
Eur J Pharm Biopharm
January 2024
Pharmaceutical Biotechnology, Department of Pharmacy, Ludwig-Maximilians-Universität Munich, Butenandtstrasse 5-13, 81377 Munich, Germany; Center for Nanoscience, Ludwig-Maximilians-Universität Munich, Geschwister-Scholl-Platz 1, 80539 Munich, Germany; CNATM - Cluster for Nucleic Acid Therapeutics Munich, Germany. Electronic address:
Messenger RNA (mRNA) is a powerful tool for nucleic acid-based therapies and vaccination, but efficient and specific delivery to target tissues remains a significant challenge. In this study, we demonstrate lipoamino xenopeptide carriers as components of highly efficient mRNA LNPs. These lipo-xenopeptides are defined as 2D sequences in different 3D topologies (bundles or different U-shapes).
View Article and Find Full Text PDF